Skip to main content
Top
Published in: Drugs & Aging 5/2000

01-11-2000 | Review Article

Differential Pharmacokinetics of Digoxin in Elderly Patients

Authors: Dr Colm G. Hanratty, Paul McGlinchey, G. Dennis Johnston, A. Peter Passmore

Published in: Drugs & Aging | Issue 5/2000

Login to get access

Abstract

Digoxin remains one of the most commonly prescribed of all cardiac medications. The main indications for digoxin usage include atrial fibrillation and heart failure; both these conditions are more prevalent in older patients. Given the aging population and the increasing incidence of heart failure we would expect prescribing of digoxin to remain as frequent or to even increase in older patients. Older patients are also more likely to develop toxicity and diagnosis of digoxin toxicity can be difficult in this group. Numerous components contribute to the development of toxicity in older patients, ranging from aging-related changes in renal function or body mass to polypharmacy and possible interactions with digoxin. It is therefore important to understand how the pharmacokinetics of digoxin may be altered in the older population. Application of basic pharmacological principles may be helpful in anticipating these problems. This review describes the pharmacokinetics of digoxin, the changes in pharmacokinetics with increasing age and how concomitant disease states or drug interactions may affect the pharmacokinetics of digoxin. Greater knowledge about the causes and prevention of digoxin toxicity should further reduce the morbidity and mortality arising from digoxin toxicity, especially in the elderly population.
Literature
1.
go back to reference Passmore AP, Crawford VL, Beringer TR, et al. Determinants of drug utilisation in an elderly population in North and West Belfast. Pharmacoepidemiol Drug Saf 1995; 4: 147–60CrossRef Passmore AP, Crawford VL, Beringer TR, et al. Determinants of drug utilisation in an elderly population in North and West Belfast. Pharmacoepidemiol Drug Saf 1995; 4: 147–60CrossRef
2.
go back to reference Smith TW. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol 1985; 5: 43–50CrossRef Smith TW. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol 1985; 5: 43–50CrossRef
3.
go back to reference Caldwell JH, Martin JF, Dutta S, et al. Intestinal absorption of digoxin-3H in the rat. Am J Physiol 1969; 217: 1747–51PubMed Caldwell JH, Martin JF, Dutta S, et al. Intestinal absorption of digoxin-3H in the rat. Am J Physiol 1969; 217: 1747–51PubMed
4.
go back to reference Cusack B, Kelly J, O’Malley K, et al. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol Ther 1979; 25: 772–6PubMed Cusack B, Kelly J, O’Malley K, et al. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol Ther 1979; 25: 772–6PubMed
5.
go back to reference Passmore AP, Johnston GD. Digoxin toxicity in the aged: characterising and avoiding the problem. Drugs Aging 1991; 1: 364–79PubMedCrossRef Passmore AP, Johnston GD. Digoxin toxicity in the aged: characterising and avoiding the problem. Drugs Aging 1991; 1: 364–79PubMedCrossRef
6.
go back to reference Sumner DJ, Russell AJ. Digoxin pharmacokinetics: multi-compartmental analysis and its clinical implications. Br J Clin Pharmacol 1976; 3: 221–9PubMedCrossRef Sumner DJ, Russell AJ. Digoxin pharmacokinetics: multi-compartmental analysis and its clinical implications. Br J Clin Pharmacol 1976; 3: 221–9PubMedCrossRef
7.
go back to reference Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996; 24: 142–7PubMed Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996; 24: 142–7PubMed
8.
go back to reference de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551–7PubMedCrossRef de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551–7PubMedCrossRef
9.
go back to reference Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49–64PubMedCrossRef Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 35: 49–64PubMedCrossRef
10.
go back to reference Castleden CM, Volans CN, Raymond K. The effect of ageing on drug absorption from the gut. Age Ageing 1977; 6: 138–43PubMedCrossRef Castleden CM, Volans CN, Raymond K. The effect of ageing on drug absorption from the gut. Age Ageing 1977; 6: 138–43PubMedCrossRef
11.
go back to reference Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155–63PubMedCrossRef Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155–63PubMedCrossRef
12.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRef
13.
go back to reference Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22: 955–62PubMedCrossRef Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22: 955–62PubMedCrossRef
14.
go back to reference Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE Study. N Engl J Med 1993; 329: 1–7PubMedCrossRef Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE Study. N Engl J Med 1993; 329: 1–7PubMedCrossRef
15.
go back to reference Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33CrossRef Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33CrossRef
16.
go back to reference Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503–6PubMed Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503–6PubMed
17.
go back to reference Galun E, Flugelman MY, Glickson M, et al. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991; 99: 1038–40PubMedCrossRef Galun E, Flugelman MY, Glickson M, et al. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991; 99: 1038–40PubMedCrossRef
18.
go back to reference Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet 1988; 15: 94–113PubMedCrossRef Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet 1988; 15: 94–113PubMedCrossRef
19.
go back to reference Borst SE, Lowenthal DT. Cardiovascular drugs in the elderly. Cardiovasc Clin 1992; 22: 161–73PubMed Borst SE, Lowenthal DT. Cardiovascular drugs in the elderly. Cardiovasc Clin 1992; 22: 161–73PubMed
20.
go back to reference Brown DD, Dormois JC, Abraham GN, et al. Effect of furosemide on the renal excretion of digoxin. Clin Pharmacol Ther 1976; 20: 395–400PubMed Brown DD, Dormois JC, Abraham GN, et al. Effect of furosemide on the renal excretion of digoxin. Clin Pharmacol Ther 1976; 20: 395–400PubMed
21.
go back to reference Hall RJ, Gelbart A, Billingham M, et al. Effect of chronic potassium depletion on digitalis-induced inotropy and arrhythmias. Cardiovasc Res 1981; 15: 98–107PubMedCrossRef Hall RJ, Gelbart A, Billingham M, et al. Effect of chronic potassium depletion on digitalis-induced inotropy and arrhythmias. Cardiovasc Res 1981; 15: 98–107PubMedCrossRef
22.
go back to reference Steiness E. Digoxin toxicity compared with myocardial digoxin and potassium concentration. Br J Pharmacol 1978; 63: 233–7PubMedCrossRef Steiness E. Digoxin toxicity compared with myocardial digoxin and potassium concentration. Br J Pharmacol 1978; 63: 233–7PubMedCrossRef
23.
go back to reference Waldorff S, Hansen PB, Egeblad H, et al. Interactions between digoxin and potassium-sparing diuretics. Clin Pharmacol Ther 1983; 33: 418–23PubMedCrossRef Waldorff S, Hansen PB, Egeblad H, et al. Interactions between digoxin and potassium-sparing diuretics. Clin Pharmacol Ther 1983; 33: 418–23PubMedCrossRef
24.
go back to reference Hedman A, Angelin B, Arvidsson A, et al. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol 1992; 42: 481–5PubMedCrossRef Hedman A, Angelin B, Arvidsson A, et al. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol 1992; 42: 481–5PubMedCrossRef
25.
go back to reference Cleland JG, Dargie HJ, Pettigrew A, et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. Am Heart J 1986; 112: 130–5PubMedCrossRef Cleland JG, Dargie HJ, Pettigrew A, et al. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. Am Heart J 1986; 112: 130–5PubMedCrossRef
26.
go back to reference Miyakawa T, Shionoiri H, Takasaki I, et al. The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. J Cardiovasc Pharmacol 1991; 17: 576–80PubMedCrossRef Miyakawa T, Shionoiri H, Takasaki I, et al. The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. J Cardiovasc Pharmacol 1991; 17: 576–80PubMedCrossRef
27.
go back to reference Doering W, Maass L, Irmisch R, et al. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. Am J Cardiol 1987; 59: 60–4CrossRef Doering W, Maass L, Irmisch R, et al. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. Am J Cardiol 1987; 59: 60–4CrossRef
28.
go back to reference Vandenburg MJ, Stephens JD, Resplandy G, et al. Digoxin pharmacokinetics and perindopril in heart failure patients. J Clin Pharmacol 1993; 33: 146–9PubMed Vandenburg MJ, Stephens JD, Resplandy G, et al. Digoxin pharmacokinetics and perindopril in heart failure patients. J Clin Pharmacol 1993; 33: 146–9PubMed
29.
go back to reference De Smet M, Schoors DF, De Meyer G, et al. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 1995; 40: 571–5PubMedCrossRef De Smet M, Schoors DF, De Meyer G, et al. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 1995; 40: 571–5PubMedCrossRef
30.
go back to reference Martin DE, Tompson D, Boike SC, et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol 1997; 43: 661–4PubMedCrossRef Martin DE, Tompson D, Boike SC, et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol 1997; 43: 661–4PubMedCrossRef
31.
go back to reference Lefebvre RA, Bogaert MG, Duprez D. et al. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin. Eur J Clin Pharmacol 1990; 38: 505–7PubMedCrossRef Lefebvre RA, Bogaert MG, Duprez D. et al. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin. Eur J Clin Pharmacol 1990; 38: 505–7PubMedCrossRef
33.
go back to reference Lowenthal DT, Porter RS, Achari R, et al. Esmolol-digoxin drug interaction. J Clin Pharmacol 1987; 27: 561–6PubMed Lowenthal DT, Porter RS, Achari R, et al. Esmolol-digoxin drug interaction. J Clin Pharmacol 1987; 27: 561–6PubMed
34.
go back to reference Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–55PubMedCrossRef Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–55PubMedCrossRef
35.
go back to reference De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990; 29: 486–90PubMedCrossRef De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990; 29: 486–90PubMedCrossRef
36.
go back to reference Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. BMJ 1978; I: 279–80CrossRef Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. BMJ 1978; I: 279–80CrossRef
37.
go back to reference Schenck-Gustafsson K, Dahlqvist R. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol 1981; 11: 181–6PubMedCrossRef Schenck-Gustafsson K, Dahlqvist R. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol 1981; 11: 181–6PubMedCrossRef
38.
go back to reference Doering W. Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med 1979; 301: 400–4PubMedCrossRef Doering W. Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med 1979; 301: 400–4PubMedCrossRef
39.
go back to reference Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glyco-protein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552–7PubMedCrossRef Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glyco-protein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552–7PubMedCrossRef
40.
go back to reference Doering W, Fichtl B, Herrmann M, et al. Quinidine-digoxin interaction: evidence for involvement of an extrarenal mechanism. Eur J Clin Pharmacol 1982; 21: 281–5PubMedCrossRef Doering W, Fichtl B, Herrmann M, et al. Quinidine-digoxin interaction: evidence for involvement of an extrarenal mechanism. Eur J Clin Pharmacol 1982; 21: 281–5PubMedCrossRef
41.
go back to reference Fenster PE, Hager WD, Perrier D, et al. Digoxin-quinidine interaction in patients with chronic renal failure. Circulation 1982; 66: 1277–80PubMedCrossRef Fenster PE, Hager WD, Perrier D, et al. Digoxin-quinidine interaction in patients with chronic renal failure. Circulation 1982; 66: 1277–80PubMedCrossRef
42.
go back to reference Angelin B, Arvidsson A, Dahlqvist R, et al. Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 1987; 17: 262–5PubMedCrossRef Angelin B, Arvidsson A, Dahlqvist R, et al. Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 1987; 17: 262–5PubMedCrossRef
43.
go back to reference Leahey EBJ, Bigger JTJ, Butler VPJ, et al. Quinidine-digoxin interaction: time course and pharmacokinetics. Am J Cardiol 1981; 48: 1141–6PubMedCrossRef Leahey EBJ, Bigger JTJ, Butler VPJ, et al. Quinidine-digoxin interaction: time course and pharmacokinetics. Am J Cardiol 1981; 48: 1141–6PubMedCrossRef
44.
go back to reference Leahey EBJ, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA 1978; 240: 533–4PubMedCrossRef Leahey EBJ, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA 1978; 240: 533–4PubMedCrossRef
45.
go back to reference Leahey EBJ, Reiffel JA, Heissenbuttel RH, et al. Enhanced cardiac effect of digoxin during quinidine treatment. Arch Intern Med 1979; 139: 519–21PubMedCrossRef Leahey EBJ, Reiffel JA, Heissenbuttel RH, et al. Enhanced cardiac effect of digoxin during quinidine treatment. Arch Intern Med 1979; 139: 519–21PubMedCrossRef
46.
go back to reference Reiffel JA, Leahey EBJ, Drusin RE, et al. A previously unrecognized drug interaction between quinidine and digoxin. Clin Cardiol 1979; 2: 40–2PubMed Reiffel JA, Leahey EBJ, Drusin RE, et al. A previously unrecognized drug interaction between quinidine and digoxin. Clin Cardiol 1979; 2: 40–2PubMed
47.
go back to reference Gessman L, Danilo PJ, Rosen MR. An electrophysiologic study of the digoxin-quinidine interaction. J Clin Pharmacol 1982; 23: 16–23 Gessman L, Danilo PJ, Rosen MR. An electrophysiologic study of the digoxin-quinidine interaction. J Clin Pharmacol 1982; 23: 16–23
48.
go back to reference Walker AM, Cody RJJ, Greenblatt DJ, et al. Drug toxicity in patients receiving digoxin and quinidine. Am Heart J 1983; 105: 1025–8PubMedCrossRef Walker AM, Cody RJJ, Greenblatt DJ, et al. Drug toxicity in patients receiving digoxin and quinidine. Am Heart J 1983; 105: 1025–8PubMedCrossRef
49.
go back to reference Moysey JO, Jaggarao NS, Grundy EN, et al. Amiodarone increases plasma digoxin concentrations. BMJ 1994; 1981: 272 Moysey JO, Jaggarao NS, Grundy EN, et al. Amiodarone increases plasma digoxin concentrations. BMJ 1994; 1981: 272
50.
go back to reference Fenster PE, White NWJ, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 1985; 5: 108–12PubMedCrossRef Fenster PE, White NWJ, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 1985; 5: 108–12PubMedCrossRef
51.
go back to reference Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111–6PubMedCrossRef Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4: 111–6PubMedCrossRef
52.
go back to reference Bajaj BP, Baig MW, Perrins EJ. Amiodarone-induced torsades de pointes: the possible facilitatory role of digoxin. Int J Cardiol 1991; 33: 335–7PubMedCrossRef Bajaj BP, Baig MW, Perrins EJ. Amiodarone-induced torsades de pointes: the possible facilitatory role of digoxin. Int J Cardiol 1991; 33: 335–7PubMedCrossRef
53.
go back to reference Leahey EBJ, Reiffel JA, Giardina EG, et al. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin: a prospective study. Ann Intern Med 1980; 92: 605–8PubMed Leahey EBJ, Reiffel JA, Giardina EG, et al. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin: a prospective study. Ann Intern Med 1980; 92: 605–8PubMed
54.
go back to reference Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. Am J Cardiol 1984; 53: 52–7CrossRef Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. Am J Cardiol 1984; 53: 52–7CrossRef
55.
go back to reference Wellens HJ, Gorgels AP, Braat SJ, et al. Effect of oral disopyramide on serum digoxin levels: a prospective study. Am Heart J 1980; 100: 934–5PubMedCrossRef Wellens HJ, Gorgels AP, Braat SJ, et al. Effect of oral disopyramide on serum digoxin levels: a prospective study. Am Heart J 1980; 100: 934–5PubMedCrossRef
56.
go back to reference Schwartz JB, Migliore PJ. Effect of nifedipine on serum digoxin concentration and renal digoxin clearance. Clin Pharmacol Ther 1984; 36: 19–24PubMedCrossRef Schwartz JB, Migliore PJ. Effect of nifedipine on serum digoxin concentration and renal digoxin clearance. Clin Pharmacol Ther 1984; 36: 19–24PubMedCrossRef
57.
go back to reference Klein HO, Lang R, Di Segni E, et al. Verapamil-digoxin interaction [letter]. N Engl J Med 1980; 303: 160–160PubMed Klein HO, Lang R, Di Segni E, et al. Verapamil-digoxin interaction [letter]. N Engl J Med 1980; 303: 160–160PubMed
58.
go back to reference Pedersen KE, Dorph-Pedersen A, Hvidt S, et al. Digoxin-verapamil interaction. Clin Pharmacol Ther 1981; 30: 311–6PubMedCrossRef Pedersen KE, Dorph-Pedersen A, Hvidt S, et al. Digoxin-verapamil interaction. Clin Pharmacol Ther 1981; 30: 311–6PubMedCrossRef
59.
go back to reference Rodin SM, Johnson BF, Wilson J, et al. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988; 43: 668–72PubMedCrossRef Rodin SM, Johnson BF, Wilson J, et al. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988; 43: 668–72PubMedCrossRef
60.
go back to reference Beltrami TR, May JJ, Bertino JSJ. Lack of effects of diltiazem on digoxin pharmacokinetics. J Clin Pharmacol 1985; 25: 390–2PubMed Beltrami TR, May JJ, Bertino JSJ. Lack of effects of diltiazem on digoxin pharmacokinetics. J Clin Pharmacol 1985; 25: 390–2PubMed
61.
go back to reference Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
62.
go back to reference Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9PubMedCrossRef Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9PubMedCrossRef
63.
go back to reference Garnett WR, Venitz J, Wilkens RC, et al. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994; 96: 84–6CrossRef Garnett WR, Venitz J, Wilkens RC, et al. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994; 96: 84–6CrossRef
64.
go back to reference Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263–5PubMedCrossRef Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263–5PubMedCrossRef
65.
go back to reference Weber P, Lettieri JT, Kaiser L, et al. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers. Clin Ther 1999; 21: 1563–75PubMedCrossRef Weber P, Lettieri JT, Kaiser L, et al. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers. Clin Ther 1999; 21: 1563–75PubMedCrossRef
66.
go back to reference Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 1999; 40: 91–8 Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 1999; 40: 91–8
67.
go back to reference Brown DD, Juhl RP, Warner SL. Effects of hypocholesterolemic interventions on digoxin bioavailability. Drug Metab Rev 1979; 9: 107–17PubMed Brown DD, Juhl RP, Warner SL. Effects of hypocholesterolemic interventions on digoxin bioavailability. Drug Metab Rev 1979; 9: 107–17PubMed
68.
go back to reference Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother 1997; 31: 1077–9PubMed Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother 1997; 31: 1077–9PubMed
69.
go back to reference Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997; 31: 864–6PubMed Nawarskas JJ, McCarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997; 31: 864–6PubMed
70.
go back to reference de Lannoy IA, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 1992; 263: 613–22 de Lannoy IA, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 1992; 263: 613–22
71.
go back to reference Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53PubMedCrossRef Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53PubMedCrossRef
72.
go back to reference Fenster PE, Comess KA, Hanson CD, et al. Kinetics of the digoxin-aspirin combination. Clin Pharmacol Ther 1982; 32: 428–30PubMedCrossRef Fenster PE, Comess KA, Hanson CD, et al. Kinetics of the digoxin-aspirin combination. Clin Pharmacol Ther 1982; 32: 428–30PubMedCrossRef
73.
go back to reference Finch MB, Johnston GD, Kelly JG, et al. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. Br J Clin Pharmacol 1984; 17: 353–5PubMedCrossRef Finch MB, Johnston GD, Kelly JG, et al. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. Br J Clin Pharmacol 1984; 17: 353–5PubMedCrossRef
74.
go back to reference Jorgensen, HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol 1991; 31: 108–10PubMedCrossRef Jorgensen, HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol 1991; 31: 108–10PubMedCrossRef
75.
go back to reference Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184–213PubMedCrossRef Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184–213PubMedCrossRef
76.
go back to reference Zoller B, Engel HJ, Faust-Tinnefeldt G, et al. An interaction study between benoxaprofen and digoxin. Eur J Rheumatol Inflamm 1982; 5: 82–6PubMed Zoller B, Engel HJ, Faust-Tinnefeldt G, et al. An interaction study between benoxaprofen and digoxin. Eur J Rheumatol Inflamm 1982; 5: 82–6PubMed
77.
go back to reference Doering W, Isbary J. Effect of tiaprofenic acid on serum digoxin concentration. Arzneimittel Forschung 1983; 33: 167–8PubMed Doering W, Isbary J. Effect of tiaprofenic acid on serum digoxin concentration. Arzneimittel Forschung 1983; 33: 167–8PubMed
78.
go back to reference Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 227–44PubMedCrossRef Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 227–44PubMedCrossRef
79.
go back to reference Crome P, Curl B, Holt D, et al. Digoxin and cimetidine: investigation of the potential for a drug interaction. Hum Toxicol 1985; 4: 391–9PubMedCrossRef Crome P, Curl B, Holt D, et al. Digoxin and cimetidine: investigation of the potential for a drug interaction. Hum Toxicol 1985; 4: 391–9PubMedCrossRef
80.
go back to reference Fraley DS, Britton HL, Schwinghammer TL, et al. Effect of cimetidine on steady-state serum digoxin concentrations. Clin Pharm 1983; 2: 163–5PubMed Fraley DS, Britton HL, Schwinghammer TL, et al. Effect of cimetidine on steady-state serum digoxin concentrations. Clin Pharm 1983; 2: 163–5PubMed
81.
go back to reference Ochs HR, Gugler R, Guthoff T, et al. Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J 1984; 107: 170–2PubMedCrossRef Ochs HR, Gugler R, Guthoff T, et al. Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J 1984; 107: 170–2PubMedCrossRef
82.
go back to reference Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569–72PubMedCrossRef Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569–72PubMedCrossRef
83.
go back to reference Miura T, Ueno K, Tanaka K, et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 1998; 38: 654–7PubMed Miura T, Ueno K, Tanaka K, et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 1998; 38: 654–7PubMed
84.
go back to reference Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al. Effect of alprazolam on digoxin kinetics and creatinine clearance. Clin Pharmacol Ther 1985; 38: 595–8PubMedCrossRef Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al. Effect of alprazolam on digoxin kinetics and creatinine clearance. Clin Pharmacol Ther 1985; 38: 595–8PubMedCrossRef
85.
go back to reference Guven H, Tuncok Y, Guneri S, et al. Age-related digoxin-alprazolam interaction. Clin Pharmacol Ther 1993; 54: 42–4PubMedCrossRef Guven H, Tuncok Y, Guneri S, et al. Age-related digoxin-alprazolam interaction. Clin Pharmacol Ther 1993; 54: 42–4PubMedCrossRef
86.
go back to reference Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46: 40–4PubMedCrossRef Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46: 40–4PubMedCrossRef
87.
go back to reference Cooper SJ, Kelly JG, Johnston GD, et al. Pharmacodynamics and pharmacokinetics of digoxin in the presence of lithium. Br J Clin Pharmacol 1984; 18: 21–5PubMedCrossRef Cooper SJ, Kelly JG, Johnston GD, et al. Pharmacodynamics and pharmacokinetics of digoxin in the presence of lithium. Br J Clin Pharmacol 1984; 18: 21–5PubMedCrossRef
Metadata
Title
Differential Pharmacokinetics of Digoxin in Elderly Patients
Authors
Dr Colm G. Hanratty
Paul McGlinchey
G. Dennis Johnston
A. Peter Passmore
Publication date
01-11-2000
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 5/2000
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200017050-00003

Other articles of this Issue 5/2000

Drugs & Aging 5/2000 Go to the issue

Review Article

Late Onset Asthma

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine